These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9789873)

  • 1. Development and in vivo assessment of a transdermal system for physostigmine.
    Benech H; Vincenti M; Fouchart F; Pruvost A; Vienet R; Istin M; Grognet JM
    Methods Find Exp Clin Pharmacol; 1998; 20(6):489-98. PubMed ID: 9789873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration.
    Somani SM; Khalique A
    Drug Metab Dispos; 1987; 15(5):627-33. PubMed ID: 2891478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic transdermal treatment with physostigmine and scopolamine against soman intoxication in guinea-pigs.
    Meshulam Y; Davidovici R; Wengier A; Levy A
    J Appl Toxicol; 1995; 15(4):263-6. PubMed ID: 7594194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of two scopolamine and physostigmine pretreatment regimens against nerve agent poisoning in the dog.
    Bonhage MR; Chilcoat CD; Li Q; Melendez V; Flournoy WS
    J Vet Pharmacol Ther; 2009 Apr; 32(2):146-53. PubMed ID: 19290944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
    Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
    Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of physostigmine in the rat after oral administration.
    Somani SM
    Biopharm Drug Dispos; 1989; 10(2):187-203. PubMed ID: 2706318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of physostigmine in man following a single application of a transdermal system.
    Walter K; Müller M; Barkworth MF; Nieciecki AV; Stanislaus F
    Br J Clin Pharmacol; 1995 Jan; 39(1):59-63. PubMed ID: 7756100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The electrostability and electrically assisted delivery of an organophosphate pretreatment (physostigmine) across human skin in vitro.
    Rowland CA; Chilcott RP
    J Control Release; 2000 Aug; 68(2):157-66. PubMed ID: 10925124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physostigmine-loaded liposomes for extended prophylaxis against nerve agent poisoning.
    Park JH; Lee JY; Kim KT; Joe HE; Cho HJ; Shin YK; Kim DD
    Int J Pharm; 2018 Dec; 553(1-2):467-473. PubMed ID: 30389473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution and pharmacokinetics of physostigmine in rat after intramuscular administration.
    Somani SM; Khalique A
    Fundam Appl Toxicol; 1986 Feb; 6(2):327-34. PubMed ID: 3699321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of physostigmine after intravenous administration in beagle dogs.
    Giacobini E; Somani S; McIlhany M; Downen M; Hallak M
    Neuropharmacology; 1987 Jul; 26(7B):831-6. PubMed ID: 3658115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.
    Utsuki T; Uchimura N; Irikura M; Moriuchi H; Holloway HW; Yu QS; Spangler EL; Mamczarz J; Ingram DK; Irie T; Greig NH
    J Pharmacol Exp Ther; 2007 Apr; 321(1):353-61. PubMed ID: 17255466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side effects of physostigmine as a pretreatment in guinea pigs.
    Philippens IH; Wolthuis OL; Busker RW; Langenberg JP; Melchers BP
    Pharmacol Biochem Behav; 1996 Sep; 55(1):99-105. PubMed ID: 8870044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of biliary excretion of physostigmine in rat.
    Boyer AW; Somani SM
    Arch Int Pharmacodyn Ther; 1985 Dec; 278(2):180-92. PubMed ID: 4096611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal patch delivery of acetylcholinesterase inhibitors.
    Moriearty PL; Thornton SL; Becker RE
    Methods Find Exp Clin Pharmacol; 1993; 15(6):407-12. PubMed ID: 8231460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic and muscle clearance of physostigmine in the rat.
    Unni LK; Somani SM
    Drug Metab Dispos; 1986; 14(2):183-9. PubMed ID: 2870892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the effects of two inhibitors on brain cholinesterase.
    Hallak M; Giacobini E
    Neuropharmacology; 1987 Jun; 26(6):521-30. PubMed ID: 3601008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
    De Sarno P; Pomponi M; Giacobini E; Tang XC; Williams E
    Neurochem Res; 1989 Oct; 14(10):971-7. PubMed ID: 2608162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze.
    Iijima S; Greig NH; Garofalo P; Spangler EL; Heller B; Brossi A; Ingram DK
    Neurosci Lett; 1992 Sep; 144(1-2):79-83. PubMed ID: 1436716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimum effective drug concentrations of a transdermal patch system containing procyclidine and physostigmine for prophylaxis against soman poisoning in rhesus monkeys.
    Cho Y; Kim WS; Hur GH; Ha YC
    Environ Toxicol Pharmacol; 2012 Jan; 33(1):1-8. PubMed ID: 22051905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.